We then set out to analyze the survival curves in patients with concomitant expression of RUNX3/H3K27me3 and found out that, as shown in Figure 9(a), in the 4 subgroups based on different expression status of RUNX3/H3K27me3, NSCLC patients with RUNX3/H3K27me3 co-expression demonstrated the best OS in comparison to that of other subgroups, with either RUNX3 or H3K27me3 expression or neither. This evidence concerns the gene RUNX3 and non-small cell lung carcinoma.